UNDERSTAND THE TOTAL MARKET SIZE AND TREATMENT OPPORTUNITIES FOR BIOMARKERS
The development of biomarker-driven therapies continues to be a major trend in oncology. As biomarkers are often clinically relevant in more than one indication, the concept of sizing eligible patient populations is evolving. With DRG Biomarker Epidemiology data and insights, the entire biomarker-defined population can be sized in minutes.
|Renal cell carinoma||x|
|Non-small-cell lung cancer||x||x||x|
|Head and neck cancer||x|
|Small-cell lung cancer||x|
|Source: Decision Resources Group|
FIRST-LINE DRUG-TREATABLE EGFR POPULATIONS
Non-small-cell lung cancer
Small-cell lung cancer
Squamous cell carcinoma of the head and neck
EPIDEMIOLOGY IS THE FOUNDATION OF MARKET FORECASTING AT ALL PHASES OF PRODUCT DEVELOPMENT AND STRATEGY
You need biomarker epidemiology data that you can trust in order to:
- Complete biomarker-driven market-sizing assessments based on patient population sizes and patient flows.
- Build the foundation of a market forecast for strategic planning for biomarker-targeting for new and existing assets.
- Understand how the patient populations for certain biomarkers will evolve over time.
- Answer any question you may have about specific subpopulations, biomarkers, and the impact of new studies.
- EGFR - Epidemiology - Mature Markets Data
- Key Findings
- Diagnosed Incidence of EGFR-Mutated Cancers per 100,000 People of All Ages in 2018 and 2028
- Patient-Flow Diagram of EGFR-Mutated Cancers in the Mature Markets in 2018
- Analysis of the Diagnosed Incidence of EGFR-Mutated Cancers in 2018 by Cancer Site
- Epidemiology Data
- Diagnosed Incident Cases
- Diagnosed Incident Cases of EGFR-Mutated NSCLC
- Diagnosed Incident Cases of EGFR-Mutated SCLC
- Diagnosed Incident Cases of EGFR-Mutated SCCHN
- Diagnosed Incident Cases of EGFR-Mutated Breast Cancer
- Diagnosed Incident Cases of EGFR-Mutated Colorectal Cancer
- Diagnosed Incident Cases of EGFR-Mutated Glioblastoma
- Diagnosed First-Line Drug-Treatable Population
- First-Line Drug-Treatable EGFR-Mutated NSCLC Population
- First-Line Drug-Treatable EGFR-Mutated SCLC Population
- First-Line Drug-Treatable EGFR-Mutated SCCHN Population
- First-Line Drug-Treatable EGFR-Mutated Breast Cancer Population
- First-Line Drug-Treatable EGFR-Mutated Colorectal Cancer Population
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Diagnosed Incident Cases
- Studies Excluded in the Analysis of Diagnosed Incident Cases
- Risk/Protective Factors
- Literature Review
Author(s): Abey John, MPH
Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.
Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.